Biomarker changes over time
| . | PLAT-02, cohort 1 . | PLAT-02, cohort 2 . | PLAT-05 . | All patients . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute-baseline (pg/mL) . | P value . | N . | Acute-baseline (pg/mL) . | P value . | N . | Acute-baseline (pg/mL) . | P value . | N . | Acute-baseline (pg/mL) . | P value . | N . | |
| cGFAP | ||||||||||||
| ICANS 0 | ∗ | 1 | ∗ | 1 | −363.7 | .0923 | 12 | −437.8 | .0295 | 14 | ||
| All ICANS | 3087 | .0210 | 12 | 622.7 | .0313 | 7 | −108.3 | .5703 | 9 | 623.6 | .0041 | 28 |
| cNfL | ||||||||||||
| ICANS 0 | ∗ | 1 | ∗ | 1 | −0.1 | .3203 | 12 | −0.1 | .2734 | 14 | ||
| All ICANS | 257 | .0049 | 12 | 261.3 | .0781 | 7 | 46.8 | .3125 | 9 | 143.2 | .0007 | 28 |
| sNfL | ||||||||||||
| ICANS 0 | 73.7 | .0249 | 24 | −25.6 | .0984 | 36 | 116.2 | .0195 | 13 | 0 | .1727 | 73 |
| All ICANS | −57.9 | .0420 | 11 | 11.1 | .8462 | 37 | −55.5 | .0078 | 9 | −19.5 | .1228 | 57 |
| . | PLAT-02, cohort 1 . | PLAT-02, cohort 2 . | PLAT-05 . | All patients . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute-baseline (pg/mL) . | P value . | N . | Acute-baseline (pg/mL) . | P value . | N . | Acute-baseline (pg/mL) . | P value . | N . | Acute-baseline (pg/mL) . | P value . | N . | |
| cGFAP | ||||||||||||
| ICANS 0 | ∗ | 1 | ∗ | 1 | −363.7 | .0923 | 12 | −437.8 | .0295 | 14 | ||
| All ICANS | 3087 | .0210 | 12 | 622.7 | .0313 | 7 | −108.3 | .5703 | 9 | 623.6 | .0041 | 28 |
| cNfL | ||||||||||||
| ICANS 0 | ∗ | 1 | ∗ | 1 | −0.1 | .3203 | 12 | −0.1 | .2734 | 14 | ||
| All ICANS | 257 | .0049 | 12 | 261.3 | .0781 | 7 | 46.8 | .3125 | 9 | 143.2 | .0007 | 28 |
| sNfL | ||||||||||||
| ICANS 0 | 73.7 | .0249 | 24 | −25.6 | .0984 | 36 | 116.2 | .0195 | 13 | 0 | .1727 | 73 |
| All ICANS | −57.9 | .0420 | 11 | 11.1 | .8462 | 37 | −55.5 | .0078 | 9 | −19.5 | .1228 | 57 |
Pairwise comparisons were performed between acute samples (CSF, days 5-15 after CAR T-cell infusion for cohorts 1 and 2, day 10 for cohort 3; serum days 7-10 for all patients) and baseline (prelymphodepletion for CSF; day 1 for serum) samples. Measurements represent the difference calculated by subtracting the baseline level from the acute level; the median is shown for each group. P values were calculated by Wilcoxon matched-pairs signed-rank test; P values <.05 are in bold.
Insufficient number of samples for statistical analysis.